You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Azithromycin and high-dose vitamin D for treatment and prevention of asthma-like episodes in hospitalised preschool children: study protocol for a combined double-blind randomised controlled trial

Responses

Article menu
Paediatrics
Protocol
Azithromycin and high-dose vitamin D for treatment and prevention of asthma-like episodes in hospitalised preschool children: study protocol for a combined double-blind randomised controlled trial
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 25 April 2022
    Infection biomarkers in asthma: Important not to miss using the best ones
    • Nikki M. Schultek, patient and patient advocate Intracell Research Group, Wake Forest, NC, USA
    • Other Contributors:
      • David L. Hahn, Clinician-Researcher
      • Thomas J. Borody, Clinician-Researcher
      • Fred A. Wagshul, Clinician
      • Wilmore C. Webley, Associate Professor of Microbiology
      • Jenny A. K. Ekberg, Associate Professor of Neurophysiology
      • James A. St. John, Associate Professor, Neurobiology
      • David B. Corry, Professor of Medicine: Allergy, Immunology, Rheumatology
      • Brian J. Balin, Professor of Neuroscience and Neuropathology
      • Or Shemesh, Assistant Professor, Neuroscience andBioengineering

    The Intracell Research Group (IRG, www.intracellresearchgroup.com) is a global research consortium consisting of microbiologists, neuroscientists, asthma clinical researchers, physicians, life sciences professionals and others advocating for the study of chronic intracellular infections as potential causes for chronic inflammatory diseases of unknown etiology with emphasis on Alzheimer’s, Asthma, Coronary Heart Disease, and Crohn’s. We wish to comment on the exciting protocol of Kyvsgaard et al.1 published recently in BMJ Open, of a 3-day treatment with azithromycin or long-term vitamin D (to affect short- and long-term symptomatology, respectively) in preschool patients hospitalized with acute asthma-like episodes. Previous work by Stokholm et al.2 in children with asthma-like symptoms found that a 3-day treatment with azithromycin was effective in the short-term but did not significantly affect the time to next episode of troublesome lung symptoms in individual children. We applaud inclusion of microbiologic measurements in the protocol and wish to point out how the investigation of associations of infection and treatment response may be augmented.

    The Kyvsgaard protocol microbiologic methods may fail to detect important atypical respiratory pathogens that are prone to produce chronic infections and that have been associated with asthma. In chronic infections, Chlamydia pneumoniae and Mycoplasma pneumoniae may re...

    Show More
    Conflict of Interest:
    None declared.